Asset Details
Do you wish to reserve the book?
Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy
Do you wish to request the book?
Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy
2013
Overview
Background
At present, the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) is still largely supportive and symptomatic. Homoharringtonine (HHT), a valid drug for treating chronic myelogenous leukemia, has shown some effect on leukemic stem cells. The aim of this study was to observe the effect of HHT on patients with high-risk PV and ET.
Methods
Patients with high-risk PV (
n
= 17) or ET (
n
= 18) who had failed or were intolerant to hydroxycarbamide or interferon-α therapy received HHT at a dose of 1.5 mg/m
2
daily by continuous infusion for 7 days every month. Hematological responses were evaluated at the 6th month after HHT therapy.
Results
After six courses of HHT therapy, the hematological response rates were 64.7 % (11/17) in PV and 72.2 % (13/18) in ET. In PV, the single sign remission rates of constitutional symptoms, symptomatic splenomegaly, pruritus and bone pain were 70.0 % (7/10), 77.8 % (7/9), 50 % (1/2) and 100 % (3/3), respectively. The remission rates of constitutional symptoms and symptomatic splenomegaly in ET were 66.7 % (6/9) and 71.4 % (5/7), respectively. The rates of grade 1 granulocytopenia and thrombocytopenia were 1.8 and 0.9 %, respectively. No grade 2 or over events, or pancytopenia were observed.
Conclusions
Low-dose HHT alone has considerable short-term efficacy for high-risk PV/ET and may used as a second-line drug for PV/ET treatment in patients who have failed or were intolerant to hydroxycarbamide or interferon-α therapy.
Publisher
Springer Japan
Subject
/ Aged
/ Dose-Response Relationship, Drug
/ Female
/ Harringtonines - administration & dosage
/ Harringtonines - adverse effects
/ Humans
/ Hydroxyurea - administration & dosage
/ Interferon-alpha - administration & dosage
/ Male
/ Medicine
/ Oncology
/ Polycythemia Vera - drug therapy
/ Polycythemia Vera - pathology
